Christopher Gill

Christopher Gill has an MD from the University of Massachusetts Medical School and an MS from Tufts-Sackler School of Graduate Biomedical Studies.Dr. Gill is an infectious disease specialist by training. From 2002-2008 he was a faculty member of the Department of Global Health at Boston University School of Public Health, engaged in a wide variety of clinical trials and investigations. His research interests have focused on child survival, and include diarrheal diseases, tuberculosis, pneumococcal and meningococcal disease, adherence to HIV medications, and neonatal survival. He was the principal investigator of the Lufwanyama Neonatal Survival Project in Northern Zambia (LUNESP), a prospective, cluster-randomized  and controlled effectiveness study designed to determine whether training traditional birth attendants to manage several common perinatal conditions could reduce neonatal mortality in the setting of a resource-poor country with limited access to healthcare. From 2008-end of 2010 he was the Director of the Meningitis ACWY conjugate vaccine clinical trials group at Novartis Vaccines. In 2011, he rejoined the faculty at the BU Center for Global Health and Development and the BU School of Public Health, working as the Director of the BUSPH Pharmaceuticals Program from 2011-15, teaching, mentoring, and conducting research in the areas of HIV medication adherence in China, advocacy around child mortality due to diarrhea and pneumonia, pertussis and RSV disease surveillance in Zambia, and capacity building of Vietnamese community health workers using SMS text messaging.